Biocon Limited has announced that its Board of Directors will meet on May 07, 2026, to evaluate a significant strategic investment in its unlisted subsidiary, Biocon Biologics Limited (BBL). The proposal involves the acquisition of equity shares in BBL through a non-cash arrangement, specifically by issuing fully paid-up equity shares of Biocon Limited on a preferential allotment basis. The final decision remains subject to necessary shareholder approvals.
Proposed Investment Details
During the upcoming board meeting scheduled for May 07, 2026, the directors of Biocon Limited are set to discuss a proposal to further consolidate its interest in Biocon Biologics Limited (BBL). This strategic move is intended to be executed through the purchase or acquisition of equity shares in the subsidiary.
Structuring the Transaction
The company plans to conduct this acquisition for a consideration other than cash. To facilitate this, the board is considering the issuance and allotment of fully paid-up equity shares of Biocon Limited. This transaction is proposed to be carried out on a preferential allotment basis through a private placement. The board will also be responsible for determining the specific issue price of these shares in compliance with established capital and disclosure requirements.
Next Steps for Shareholders
Following the board’s decision and deliberations, the company intends to seek the necessary approval from shareholders to finalize the transaction. This will be facilitated through a Postal Ballot process. Further details regarding the notice and the specific timeline for the ballot will be disclosed to the exchanges in due course.
Source: BSE
